These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29109015)

  • 1. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
    He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
    Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
    Todorov K; Wilson C; Sharplin G; Corsini N
    Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of FOB testing in eastern-Australian general practice patients: what has a national bowel cancer screening program delivered?
    Paul CL; Carey ML; Russell G; D'Este C; Sanson-Fisher RW; Zwar N
    Health Promot J Austr; 2015 Apr; 26(1):39-44. PubMed ID: 25818504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engaging lower screening groups: a field experiment to evaluate the impact of a multiwave national campaign on participation in the National Bowel Cancer Screening Program.
    Gascoyne C; Broun K; Morley B; Wyatt K; Feletto E; Durkin SJ
    BMJ Open; 2023 Mar; 13(3):e065124. PubMed ID: 36921953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact of the Australian National Bowel Cancer Screening Programme.
    Ananda S; Wong H; Faragher I; Jones IT; Steele M; Kosmider S; Desai J; Tie J; Field K; Wong R; Tran B; Bae S; Gibbs P
    Intern Med J; 2016 Feb; 46(2):166-71. PubMed ID: 26418334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
    Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
    Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial impact of Australia's National Bowel Cancer Screening Program.
    Ananda SS; McLaughlin SJ; Chen F; Hayes IP; Hunter AA; Skinner IJ; Steel MC; Jones IT; Hastie IA; Rieger NA; Shedda S; Compston DJ; Gibbs P
    Med J Aust; 2009 Oct; 191(7):378-81. PubMed ID: 19807627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trust, choice and obligation: a qualitative study of enablers of colorectal cancer screening in South Australia.
    Ward PR; Coffey C; Meyer S
    Sociol Health Illn; 2015 Sep; 37(7):988-1006. PubMed ID: 25912247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program.
    Cole SR; Tucker GR; Osborne JM; Byrne SE; Bampton PA; Fraser RJ; Young GP
    Med J Aust; 2013 Apr; 198(6):327-30. PubMed ID: 23545032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a mass media campaign on participation rates in a National Bowel Cancer Screening Program: a field experiment.
    Durkin SJ; Broun K; Spittal MJ; Wakefield MA
    BMJ Open; 2019 Jan; 9(1):e024267. PubMed ID: 30813110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of re-participation in faecal occult blood test- based screening for colorectal cancer.
    Cole SR; Gregory T; Whibley A; Ward P; Turnbull D; Wilson C; Flight I; Esterman A; Young GP
    Asian Pac J Cancer Prev; 2012; 13(12):5989-94. PubMed ID: 23464391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.